Vanderbilt University Medical Center is evaluating razuprotafib, a drug being investigated for the treatment of glaucoma, in a new randomized, investigational trial for the prevention and treatment of acute respiratory distress syndrome (ARDS) in adult patients with moderate to severe COVID-19.
“We urgently need to find effective treatments for COVID-19, especially for patients who develop severe lung injury from the virus,” said co-principal investigator Wesley Self, MD, an emergency medicine physician at Vanderbilt University Medical Center.